The Binding Site Group, a privately-owned specialist UK diagnostics company, has announced the sale of its autoimmune diagnostics business to the Werfen Group, based in Barcelona, Spain. The autoimmune diagnostics business develops, manufactures and distributes a range of diagnostic assays and reagents used in hospital laboratories worldwide to help diagnose and monitor the treatment of autoimmune diseases including rheumatoid arthritis, antiphospholipid syndrome, vasculitis and coeliac disease.
Under the agreement, The Binding Site will continue to manufacture autoimmune products on behalf of the Werfen Group, enabling Werfen to continue servicing The Binding Site autoimmune business worldwide without disruption to clients. The protein business of The Binding Site, including Freelite and Hevylite will be unaffected by this acquisition and will carry on being manufactured, developed and marketed by The Binding Site.
Paul Duncan, chief executive officer of The Binding Site, said: “The Binding Site has built a strong niche in the autoimmune sector. We are confident that a company of the calibre of Werfen will be well placed to continue to deliver the level of quality and service that our customers have come to expect, and we look forward to working closely with Werfen and our customers to ensure a smooth transition over the coming months.”
www.bindingsite.co.uk